Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
Union health ministry secretary Punya Salila Srivastava lauds HLL’s six decades of contribution to public healthcare and social development
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The company reported free cash flow of Rs. 2,590 Mn for FY26
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
